Correspondence 0001213900-24-107611 from Radiopharm Theranostics Ltd (RADX, RDPTF) (CIK 0001949257) (RADX)
Radiopharm Theranostics Ltd (RADX, RDPTF) (CIK 0001949257)
Date: Dec. 11, 2024 · CIK: 0001949257 · Accession: 0001213900-24-107611
AI Filing Summary & Sentiment
File numbers found in text: 333-283627
Letter
Re: Radiopharm Theranostics Limited
December 11, 2024
via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Registration Statement on Form F-1
Filed December 5, 2024
File No. 333-283627
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, Radiopharm Theranostics Limited (the “Registrant”) respectfully requests acceleration of its Registration Statement on Form F-1 (File No. 333-283627), filed on December 5, 2024, so that it will become effective at 9:00 a.m. (Eastern time) on December 13, 2024, or as soon as practicable thereafter.
If you have any questions, or require any additional information, please do not hesitate to email Andrew Reilly, the Registrant’s outside counsel, at andrew.reilly@rimonlaw.com.
The Registrant acknowledges that, if the Securities and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective, such action:
(i) does not foreclose the Commission from taking any action with respect to the filing;
(ii) does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) may not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very truly yours,
Radiopharm Theranostics Limited
Show Raw Text
CORRESP
1
filename1.htm
December 11, 2024
via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re:
Radiopharm Theranostics Limited
Registration Statement on Form F-1
Filed December 5, 2024
File No. 333-283627
Request for Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities
Act of 1933, Radiopharm Theranostics Limited (the “Registrant”) respectfully requests acceleration of its Registration Statement
on Form F-1 (File No. 333-283627), filed on December 5, 2024, so that it will become effective at 9:00 a.m.
(Eastern time) on December 13, 2024, or as soon as practicable thereafter.
If you have any questions, or require any
additional information, please do not hesitate to email Andrew Reilly, the Registrant’s outside counsel, at andrew.reilly@rimonlaw.com.
The Registrant acknowledges that, if the Securities
and Exchange Commission (or its staff, acting pursuant to delegated authority) (the “Commission”) declares the filing effective,
such action:
(i) does
not foreclose the Commission from taking any action with respect to the filing;
(ii) does
not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
(iii) may
not be asserted by the Registrant as a defense in any proceeding initiated by the Commission or any person under the federal securities
laws of the United States.
Very truly yours,
Radiopharm Theranostics Limited
/s/ Riccardo Canevari
Riccardo Canevari
Chief Executive Officer and
Managing Director